18P Baseline and dynamic changes in haemoglobin levels predict treatment response and disease progression in metastatic renal cell carcinoma

Y-H Yang,A Meerveld-Eggink,A Bex,F Jackson-Spence,K.S Rallis,P.R Brian,J Choy,C.C Sng,P Adeniran,J Amin,S Galope,N Anderson,S Fernandezgomez,T.B Powles,B.E Szabados

doi:10.1016/j.annonc.2022.01.026

18P Baseline and dynamic changes in haemoglobin levels predict treatment response and disease progression in metastatic renal cell carcinoma

Y-H Yang, A Meerveld-Eggink + Show 13 more

Open Access

https://doi.org/10.1016/j.annonc.2022.01.026

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Mar 1, 2022
License type: publisher-specific-oa

Affiliation: Barts Health NHS Trust, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Royal Free London NHS Foundation Trust

#Metastatic Renal Cell Carcinoma #Changes In Haemoglobin + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Early clinical markers of response to first-line treatment with immune checkpoint inhibitors (ICI) and VEGF inhibitors (VEGFI) in metastatic renal cell carcinoma (mRCC) are lacking. We explore whether baseline and dynamic changes in haemoglobin (Hb) is associated with treatment response and disease progression.

Full Text